Botulinum toxin in the management of childhood muscle spasticity: Comparison of clinical practice of 17 treatment centres

European Journal of Neurology

Volumn 10, Issue 4, 2003, Pages 415-419

  Bakheit, A M O ^a,b  

^a PENINSULA MEDICAL SCHOOL   (United Kingdom)

^b Mount Gould Hospital   (United Kingdom)

Author keywords

Botulinum toxin type A; Spasticity

Indexed keywords

BOTULINUM TOXIN A; ANTIPARKINSON AGENT;

ARTICLE; CEREBRAL PALSY; CHILD; CLINICAL PRACTICE; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; GENERAL ANESTHESIA; HUMAN; MAJOR CLINICAL STUDY; OPEN STUDY; OPTIMAL DRUG DOSE; PHYSICIAN; PRIORITY JOURNAL; SEDATION; SPASTICITY; TREATMENT OUTCOME; ANESTHESIA; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; DRUG COMBINATION; EUROPE; EVALUATION; FEMALE; INTRAMUSCULAR DRUG ADMINISTRATION; MALE; MULTICENTER STUDY; PAIN; RANDOMIZED CONTROLLED TRIAL; RETROSPECTIVE STUDY; STANDARD; THERAPY;

ANESTHESIA; ANTI-DYSKINESIA AGENTS; BOTULINUM TOXIN TYPE A; CEREBRAL PALSY; CHILD; DRUG THERAPY, COMBINATION; EUROPE; EVALUATION STUDIES; FEMALE; HUMANS; INJECTIONS, INTRAMUSCULAR; MALE; MULTICENTER STUDIES; MUSCLE SPASTICITY; PAIN; RANDOMIZED CONTROLLED TRIALS; RETROSPECTIVE STUDIES; THERAPEUTICS; TREATMENT OUTCOME;

EID: 0041784760     PISSN: 13515101     EISSN: 14681331     Source Type: Journal    
DOI: 10.1046/j.1468-1331.2003.00619.x     Document Type: Article

References (12)

1. Bakheit AMO (2001). Botulinum Toxin Treatment of Muscle Spasticity. Blackhall Publishers, Dublin.
2. Bakheit AMO, Severa S, Cosgrove A et al. (2001). The safety profile and efficacy of botulinum toxin type A (Dysport) in children with muscle spasticity. Dev Med Child Neurol 43:234-238.
3. Borodic GE, Ferrante R, Pearce BL, Smith K (1994). Histologic assessment of dose-related diffusion and muscle fibre response after therapeutic botulinum A toxin injections. Mov Disord 9:31-39.
4. Calderon-Gonzalez R, Calderon-Sepulveda R, Rincon-Reyes M, Garcia-Ramirez J, Mino-Arango E (1994). Botulinum toxin A in management of cerebral palsy. Pediatr Neurol 10:284-288.
5. Corry IS, Cosgrove AP, Duffy CM, Taylor TC, Graham HK (1999). Botulinum toxin A in hamstring spasticity. Gait Posture 10:206-210.
6. Cosgrove AP, Corry IS, Graham HK (1994). Botulinum toxin in the management of the lower limb in cerebral palsy. Dev Med Child Neurol 36:386-389.
7. Koman AL, Mooney JF, Smith BP, Goodman A, Mulvaney T (1994). Botulinum toxin type A management of spasticity in cerebral palsy with botulinum toxin: a report of a preliminary randomised double-blind trial. J Paediatr Orthop 14:299-303.
8. Koman AL, Mooney JF III, Smith BP, Walker F, Leon JM (2000). Botulinum toxin type A neuromuscular blockade in the treatment of lower extremity spasticity in cerebral palsy: a randomised double-blind, placebo-controlled trial. J Paediatr Orthop 20:108-115.
9. Ljungman G, Kreuger A, Andreasson S, Gordh T, Sorensen S (2000). Midazolam nasal spray reduces procedural anxiety in children. Pediatrics 105:73-78
10. Massin M, Alington N (1999). Role of exercise testing in the functional assessment of cerebral palsy children after botulinum A toxin injection. J Paediatr Orthop 19:362-365.
11. Nelson KB, Ellenberg JH (1978). Epidemiology of cerebral palsy In: Schoenberg BS, ed. Advances in Neurology, Vol. 19. Raven Press, New York, pp. 421-435.
12. Sutherland DH, Kaufman KR, Wyatt MP, Chambers HG (1996). Injection of botulinum toxin A into the gastrocnemius muscle in patients with cerebral palsy: a 3-dimensional motion analysis study. Gait Posture 4:269-279.